Literature DB >> 21927028

Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway.

J K Woo1, Y Choi, S-H Oh, J-H Jeong, D-H Choi, H-S Seo, C-W Kim.   

Abstract

Although the hyper-glycosylated transmembrane protein Mucin 1 (MUC1) is aberrantly overexpressed in human breast carcinoma, the biological significance of MUC1 overexpression is unclear. This study showed that MUC1 expression promoted the synthesis and secretion of vascular endothelial growth factor (VEGF) through the AKT signaling pathway. Increase VEGF production through MUC1 expression had a number of effect. First, MUC1 transfection increased expression of VEGF in breast cancer cells. Second, MUC1-mediated VEGF induction was attenuated by a chemical inhibitor of AKT or MUC1 knock-down by MUC1 siRNA. Third, MUC1 expression led to the activation of insulin-like growth factor-1 receptor, which correlated with VEGF expression. In addition, when MDA-MB-231 human breast cancer cells were directly injected into NOD/SCID mice, MUC1 expression accelerated xenograft tumor growth in vivo. Finally, MUC1 expression enhanced tumor growth and angiogenesis in a PyMT-MMTV/hMUC1 transgenic mouse model. Concurrent with these results, analysis of a human tissue microarray identified a high correlation between MUC1 and VEGF expression in human breast carcinoma. The current report is the first to demonstrate that MUC1 expression promotes angiogenesis in human breast cancer in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21927028     DOI: 10.1038/onc.2011.410

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

2.  β2-AR signaling controls trastuzumab resistance-dependent pathway.

Authors:  D Liu; Z Yang; T Wang; Z Yang; H Chen; Y Hu; C Hu; L Guo; Q Deng; Y Liu; M Yu; M Shi; N Du; N Guo
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

Review 3.  Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer.

Authors:  Jos P M van Putten; Karin Strijbis
Journal:  J Innate Immun       Date:  2017-01-05       Impact factor: 7.349

4.  The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women.

Authors:  Jalila Rahoui; Yassir Sbitti; Nadia Touil; Abdelilah Laraqui; Azeddine Ibrahimi; Brahim Rhrab; Abderrahman Al Bouzidi; Driss Moussaoui Rahali; Mohamed Dehayni; Mohamed Ichou; Fatima Zaoui; Saad Mrani
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

Review 5.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

Review 6.  MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.

Authors:  D W Kufe
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

Review 7.  MUC1: a multifaceted oncoprotein with a key role in cancer progression.

Authors:  Sritama Nath; Pinku Mukherjee
Journal:  Trends Mol Med       Date:  2014-03-22       Impact factor: 11.951

8.  MiR-140-5p inhibits cell proliferation and metastasis by regulating MUC1 via BCL2A1/MAPK pathway in triple negative breast cancer.

Authors:  Bofan Yu; Wei You; Guang Chen; Yang Yu; Qinheng Yang
Journal:  Cell Cycle       Date:  2019-08-14       Impact factor: 5.173

9.  Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.

Authors:  Sritama Nath; Lopamudra Das Roy; Priyanka Grover; Shanti Rao; Pinku Mukherjee
Journal:  Pancreas       Date:  2015-08       Impact factor: 3.327

Review 10.  MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.

Authors:  Wenqing Chen; Zhu Zhang; Shiqing Zhang; Peili Zhu; Joshua Ka-Shun Ko; Ken Kin-Lam Yung
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.